HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution.
HER2
affibody molecule
cancer
half-life extension
pseudomonas exotoxin A
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 Apr 2020
24 Apr 2020
Historique:
received:
27
03
2020
revised:
20
04
2020
accepted:
22
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
30
4
2020
Statut:
epublish
Résumé
The human epidermal growth factor receptor 2 (HER2) is a clinically validated target for cancer therapy, and targeted therapies are often used in regimens for patients with a high HER2 expression level. Despite the success of current drugs, a number of patients succumb to their disease, which motivates development of novel drugs with other modes of action. We have previously shown that an albumin binding domain-derived affinity protein with specific affinity for HER2, ADAPT
Identifiants
pubmed: 32344762
pii: pharmaceutics12040391
doi: 10.3390/pharmaceutics12040391
pmc: PMC7238247
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : VINNOVA
ID : 2019/00104
Organisme : Cancerfonden
ID : CAN 2015/746, CAN 2017/425, CAN 2018/436 and CAN 2018/82
Références
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
Bioconjug Chem. 2015 Jun 17;26(6):1120-8
pubmed: 25997032
Int J Oncol. 2019 Jul;55(1):309-319
pubmed: 31180549
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6
pubmed: 18678888
Cell Mol Life Sci. 2013 Oct;70(20):3973-85
pubmed: 23728098
Tumour Biol. 2006;27(4):201-10
pubmed: 16651854
Trends Biotechnol. 2017 Aug;35(8):691-712
pubmed: 28514998
Methods Mol Biol. 2004;248:503-18
pubmed: 14970517
Cancer Res. 2007 Mar 15;67(6):2773-82
pubmed: 17363599
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3597-603
pubmed: 23213206
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Biochem Biophys Res Commun. 2008 Dec 12;377(2):489-494
pubmed: 18930032
PLoS One. 2014 Aug 04;9(8):e103094
pubmed: 25089830
Cancer Res. 2015 Oct 15;75(20):4364-71
pubmed: 26297736
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742-7
pubmed: 21436054
Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e49-57
pubmed: 20951604
Oncotarget. 2016 May 24;7(21):29916-26
pubmed: 27167198
Leukemia. 2018 Aug;32(8):1768-1777
pubmed: 30030507
Nat Rev Immunol. 2007 Sep;7(9):715-25
pubmed: 17703228
Int J Oncol. 2015 Feb;46(2):513-20
pubmed: 25434612
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
pubmed: 16829981
Immunol Rev. 2016 Mar;270(1):152-64
pubmed: 26864110
J Mol Biol. 2010 Apr 30;398(2):232-47
pubmed: 20226194
Protein Eng Des Sel. 2011 Apr;24(4):385-96
pubmed: 21177282
J Control Release. 2018 Oct 28;288:84-95
pubmed: 30172673
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11782-7
pubmed: 22753489
Cancer Res. 2006 Apr 15;66(8):4339-48
pubmed: 16618759
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Int J Oncol. 2015 Aug;47(2):601-9
pubmed: 26046132
Leuk Res. 2014 Oct;38(10):1224-9
pubmed: 25127689
Nat Commun. 2016 Jun 03;7:11672
pubmed: 27255951
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15039-44
pubmed: 20696930
Eur J Pharm Biopharm. 2019 Jan;134:37-48
pubmed: 30408518
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Appl Radiat Isot. 2006 Jan;64(1):32-7
pubmed: 16055339
Biochem Biophys Res Commun. 2016 Jun 17;475(1):93-9
pubmed: 27178207
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Biotechnol Appl Biochem. 2010 Feb 25;55(2):99-109
pubmed: 20088825
Clin Cancer Res. 2011 Aug 1;17(15):5071-81
pubmed: 21791637
MAbs. 2016 May-Jun;8(4):659-71
pubmed: 27045800
Drugs. 2020 Apr;80(5):501-508
pubmed: 32144719
Protein Eng Des Sel. 2007 Apr;20(4):189-99
pubmed: 17452435
Protein Eng Des Sel. 2008 Aug;21(8):515-27
pubmed: 18499681